- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07587632
Natural Cervical Ripening to Prevent Pharmacological Induction of Labor - a Pilot Study. (Cervinat)
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Approximately 25% of vaginal births currently occur following induction of labor (IOL). At the University Hospital Zurich, internal guidelines recommend IOL at 40 weeks of gestation for women with non-insulin-dependent, diet-controlled gestational diabetes. However, IOL may be associated with side effects and a less positive birth experience. Alternative, natural methods for cervical ripening in an outpatient setting may help promote spontaneous labor onset and reduce the need for medical induction.
This investigator-initiated, mono-centric, prospective, randomized controlled trial aims to evaluate the effectiveness, safety, and feasibility of natural cervical ripening methods, specifically nipple stimulation (breast massage/colostrum harvesting) and membrane sweeping. The primary objective is to assess whether these interventions shorten the time from 37 weeks of gestation (start of intervention) to the onset of spontaneous labor.
The primary endpoint is the time interval between 37 weeks' gestation and spontaneous onset of labor. Secondary endpoints include the rate of spontaneous labor before planned IOL, oxytocin use during childbirth, use of pharmacological induction agents, duration of hospitalization, postpartum hemorrhage (>500 ml), mode of birth, patient satisfaction with the intervention/induction and birth experience, and neonatal outcomes.
The study includes 74 pregnant women aged ≥18 years with singleton pregnancies, diet-controlled gestational diabetes, planned vaginal birth, and scheduled IOL at 40 weeks, who can communicate in German or English and have provided informed consent. Key exclusion criteria include multiple gestation, fetal growth abnormalities, insulin-dependent diabetes, planned cesarean section, onset of labor prior to enrollment, or inability to comply with study procedures.
Participants are randomized to either an intervention group or a control group. The intervention group receives membrane sweeping twice weekly by medical personnel from 37 weeks, breast massage/nipple stimulation performed by the participant for 60 minutes on three days per week, and standard colostrum harvesting beginning at 36 weeks. The control group receives standard care only, consisting of colostrum harvesting twice daily from 36 weeks, which is already routine practice at the institution.
Data collection includes questionnaires during the intervention phase (assessing experience, compliance, and side effects) and after delivery (assessing satisfaction with the intervention or IOL and overall birth experience). Recruitment takes place during routine prenatal visits or at the lactation outpatient clinic of the University Hospital Zurich. Following informed consent and confirmation of eligibility, participants are enrolled and randomized.
The anticipated benefits include increased spontaneous onset of labor, reduced need for IOL and oxytocin, decreased postpartum hemorrhage, and improved maternal satisfaction with the birth experience. Given the natural nature of the interventions, risks are considered low, primarily mild vaginal bleeding or discomfort during membrane sweeping.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Verena Bossung, PD Dr. med.
- Número de teléfono: +44 43 253 28 47
- Correo electrónico: verena.bossung@usz.ch
Copia de seguridad de contactos de estudio
- Nombre: Nicole Ochsenbein, Prof. Dr. med
- Número de teléfono: +41 43 255 51 01
- Correo electrónico: Nicole.Ochsenbein@usz.ch
Ubicaciones de estudio
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Suiza, 8091
- Reclutamiento
- University Hospital Zurich
-
Contacto:
- Nicole Ochsenbein, Prof. Dr. med
- Número de teléfono: +41 43 255 51 01
- Correo electrónico: Nicole.Ochsenbein@usz.ch
-
Contacto:
- Verena Bossung, PD Dr. med
- Número de teléfono: +44 43 253 28 47
- Correo electrónico: verena.bossung@usz.ch
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Singleton gestation
- Non-insulin dependent, dietetically managed gestational diabetes
- Greater than or equal to 34 weeks.
- Planned vaginal birth at the University Hospital of Zurich
- Planned IOL for 40 weeks of gestation.
- Communication in German and/or English language possible.
Exclusion Criteria:
- Pregnant women with multiple gestation
- Fetal macrosomia >95th percentile
- Intrauterine growth restriction <3rd percentile
- Already in labor (regular contractions or premature rupture of membranes (PROM)
- Patients scheduled for IOL before 40 weeks
- Insulin-dependent diabetes
- Planned cesarean section
- Planned birth in an external hospital
- Inability to follow the procedures e.g. due to language problems, psychological disorders
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Study Intervention
Membrane sweeping twice weekly plus intensified breast massage in addition to colostrum banking
|
Study intervention:
|
|
Sin intervención: Control arm
Standard of care treatment including colostrum banking
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
the time interval between 37/0 weeks of gestation and the onset of labor.
Periodo de tiempo: Between 37/0 weeks of gestation until the onset of labor
|
Between 37/0 weeks of gestation until the onset of labor
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Verena Bossung, PD. Dr. med., University of Zurich
Publicaciones y enlaces útiles
Publicaciones Generales
- Declercq ER, Sakala C, Corry MP, Applebaum S, Herrlich A. Major Survey Findings of Listening to Mothers(SM) III: Pregnancy and Birth: Report of the Third National U.S. Survey of Women's Childbearing Experiences. J Perinat Educ. 2014 Winter;23(1):9-16. doi: 10.1891/1058-1243.23.1.9.
- Witkop CT, Neale D, Wilson LM, Bass EB, Nicholson WK. Active compared with expectant delivery management in women with gestational diabetes: a systematic review. Obstet Gynecol. 2009 Jan;113(1):206-217. doi: 10.1097/AOG.0b013e31818db36f.
- Zanardo V, Bertin M, Sansone L, Felice L. The adaptive psychological changes of elective induction of labor in breastfeeding women. Early Hum Dev. 2017 Jan;104:13-16. doi: 10.1016/j.earlhumdev.2016.10.007. Epub 2016 Nov 30.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades del sistema endocrino
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades metabólicas
- Complicaciones del embarazo
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Enfermedades Nutricionales y Metabólicas
- Diabetes Gestacional
Otros números de identificación del estudio
- 2025-01367
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .